Buchang Pharmaceutical, a leading private Chinese medicine company (603858. SH) was accepted for clinical trial of the investigational variety.
Recently, the clinical trial application for the new indication of the new indication of the variety "BC008-1A injection" under development by Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., a subsidiary of Buchang Pharmaceutical, was accepted by the State Food and Drug Administration, and the proposed indications are glioblastoma, non-small cell lung cancer, esophageal cancer and other advanced solid tumors.
As of March 31, 2024, Buchang Pharmaceutical has invested about 75.8128 million yuan in R&D expenses on this project. At present, there are no similar dual-target drugs approved for marketing at home and abroad.
It is worth noting that on April 26, Buchang Pharmaceutical released its 2023 annual report, which showed that the company's operating income was 13.245 billion yuan, and the net profit was 319 million yuan, a year-on-year increase of 120.85%, turning losses into profits.
The R&D investment of the project exceeded 75.81 million
After 30 years of hard work, Buchang Pharmaceutical has reached the first square in patented traditional Chinese medicine, with 70 exclusive drugs.
In recent years, based on the cardiovascular and cerebrovascular market, Buchang Pharmaceutical has relied on the advantages of the main track of traditional Chinese medicine, and is also transforming in the direction of great health, from Chinese patent medicine to biological drugs, vaccines, chemical drugs, medical devices, Internet medicine and other fields, and gradually accelerating the pace of globalization. At present, Buchang Pharmaceutical has formed a three-dimensional product pattern based on the cardiovascular and cerebrovascular market, covering the traditional advantageous areas of Chinese patent medicine, focusing on major diseases and cultivating large varieties.
Recently, the clinical trial application for the new indication of the new indication of the variety "BC008-1A injection" under development by Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., a subsidiary of Buchang Pharmaceutical, was accepted by the State Food and Drug Administration, and the proposed indications are glioblastoma, non-small cell lung cancer, esophageal cancer and other advanced solid tumors.
As of March 31, 2024, Buchang Pharmaceutical has invested about 75.8128 million yuan in R&D expenses on this project. At present, there are no similar dual-target drugs approved for marketing at home and abroad.
In addition, the company's new product Xuanlung sepsis granules have also continuously achieved new progress.
It is understood that the Xuanlung Sepsis Granules were developed by Academician Zhang Boli of the Chinese Academy of Engineering and Professor Liu Qingquan of Beijing Hospital of Traditional Chinese Medicine, which has the effects of Xuanlung dampness, heat and evil, and lung detoxification. A number of studies have confirmed that Xuanlung sepsis granules can effectively inhibit viruses and bacteria, regulate immunity, inhibit inflammatory factors, protect target organs, and have a strong effect of "promoting lung inflammation absorption", and have a good therapeutic effect on COPD to improve CT indicators, improve cough, suffocation and shortness of breath.
Buchang Pharmaceutical's 2023 annual report shows that Buchang Pharmaceutical currently has 473 valid patents and 216 products under development, and its leading products are Naoxintong Capsule, Wenxin Granules, Danhong Injection, Prostastositol Capsule, Headache Ning Capsule, Kang Women's Inflammation Capsule, Milk Dispersion Capsule, Tongmai Hypoglycemic Capsule, etc. For these patented products, Buchang Pharmaceutical is also constantly developing new patents to extend the protection period.
In the field of chemical drugs, Buchang Pharmaceutical actively invests in original drugs and actively screens chemical drugs with clear targets.
At present, 17 biological products are under development, and some projects have entered the clinical phase I to III stage, covering tumors, blood diseases and osteoporosis and other therapeutic areas. In the field of vaccines, the company has 5 vaccine products, and other products such as quadrivalent influenza virus split vaccine (chicken embryo, adult type), quadrivalent influenza virus split vaccine (MDCK cell), live attenuated varicella vaccine, and live attenuated herpes zoster vaccine are under development.
In terms of performance, under the guidance of the strategy of "expanding to biopharmaceuticals, vaccines and other pharmaceutical high-tech industries based on traditional Chinese medicine", on April 26, Buchang Pharmaceutical released its 2023 annual report, which showed that the company's operating income was 13.245 billion yuan, and the net profit was 319 million yuan, a year-on-year increase of 120.85%, turning losses into profits.
Actively give back to the community
"A true entrepreneur must have a strong sense of social responsibility. To rush to the front line at a critical moment, we must assume social responsibility and give back to the society with little by little actions. Zhao Tao, chairman of Buchang Pharmaceutical, once said.
As a leader in the traditional Chinese medicine industry, Buchang Pharmaceutical firmly fulfills its social responsibilities. According to the data, since its inception (establishment - March 31, 2024), the company has paid a total of 30.495 billion yuan in taxes nationwide, including 16.973 billion yuan in Shandong Park, 3.269 billion yuan in Northeast Park, 1.475 billion yuan in Baoding Tianhao, 7.712 billion yuan in Shaanxi, and 438 million yuan in Qionglai Tianyin, making important contributions to the sustainable and steady development of the local economy.
At the same time, the company also gives back to investors by actively repurchasing shares and dividends.
On December 14, 2023, the company announced that the company's current share price does not reflect the company's long-term value and excellent asset quality, which has an impact on the company's good market image. In order to fully safeguard the interests of the company and investors, stabilize investor expectations, enhance market confidence, and promote the reasonable return of the company's stock value, based on the confidence in the company's future development prospects and the high recognition of the company's value, the company intends to repurchase shares with its own funds through centralized bidding transactions.
From December 14, 2023 to April 24, 2024, the company has repurchased a total of 10,546,300 shares of the company through centralized bidding transactions, with the repurchased shares accounting for 0.95% of the company's total share capital, the highest purchase price is 17.44 yuan/share, the lowest price is 14.16 yuan/share, and the total amount paid is 168 million yuan (excluding transaction costs).
Since its listing, Buchang Pharmaceutical has paid a total of 8.475 billion yuan in cash dividends (including repurchases) (the profit distribution in 2023 will be implemented after the approval of the general meeting of shareholders), exceeding the raised funds by 4.575 billion yuan (3.9 billion yuan of raised funds).
Not only that, in 2008, Buchang Pharmaceutical launched the public welfare activity of "Concentric and Jointly Forge China's Heart". Over the past 10 years, the public welfare activities have covered the five key Tibet-related areas in China, with 22,000 experts and professors from all over the country providing free medical assistance and free surgery to 514,000 Tibetan and other ethnic minority compatriots. So far, nearly 3,000 training sessions have been conducted for medical personnel in the recipient areas, covering more than 100,000 people. Carry out health science lectures for more than 200,000 people of all ethnic groups; It has provided free surgical treatment for nearly 3,000 children with congenital heart disease, and treated and rescued nearly 1,000 patients with hepatic echinococcosis who have been diagnosed and documented and meet the conditions for surgery.
Zhao Jing, vice chairman of Buchang Pharmaceutical, once said: "The success of the enterprise comes from its own efforts, but also benefits from the great era, the great cause and the great party. As beneficiaries, we are always grateful and consciously fulfill our responsibilities. Don't forget the original intention, you have to always. ”
It is worth mentioning that the spirit of serving the people and giving back to the society has also penetrated into the front line of each subsidiary of Buchang Pharmaceutical. On the morning of April 29, Shandong Province celebrated the "May Day" International Labor Day and the Provincial May Day Labor Award Winners Commendation Conference was grandly held, and Shandong Danhong Pharmaceutical Co., Ltd. won the 2024 Shandong May Day Labor Award.
At the same time, after a comprehensive review jointly organized by the Jilin Provincial Department of Human Resources and Social Security and the Jilin Provincial Federation of Trade Unions, the extraction team of Tonghua Guhong Pharmaceutical Co., Ltd. won the honorary title of "Jilin Provincial Worker Pioneer".